Reported about 14 hours ago
MapLight Therapeutics Inc., a biotech firm focused on treatments for neurological disorders, has successfully raised $258.9 million through an IPO and private placement, marking it as the first public offering to occur since the U.S. government shutdown. The company sold 14.75 million shares at $17 each, with additional investments from Goldman Sachs affiliates. Following the IPO, MapLight's market value is estimated at $704.3 million, as it continues to advance in its clinical trials for schizophrenia and Alzheimer's disease psychosis.
Source: YAHOO